The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
|Videos|September 30, 2019
Dr. Djouder on the Role of Liver Regeneration in HCC
Author(s)Nabil Djouder, PhD
Nabil Djouder, PhD, discusses the role of liver regeneration in hepatocellular carcinoma.
Advertisement
Nabil Djouder, PhD, head of the Growth Factors, Nutrients and Cancer Group at CNIO Cancer Center in Madrid, Spain, discusses the role of liver regeneration in hepatocellular carcinoma (HCC).
Cirrhosis is believed to be a risk factor for HCC. However, Djouder believes liver regeneration resulting from cirrhosis may act as a protective mechanism from HCC.
Djouder adds that drugs that block IL-17a, a proinflammatory cytokine, could aid in treatment of nonalcoholic steatohepatitis and HCC.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Results from an early-stage clinical trial found encouraging outcomes in newly diagnosed pancreatic cancer that had spread to distant organs.
Read a refresh of GI cancer FDA news from August 2026, including the approval of a RAS(ON) inhibitor in metastatic pancreatic cancer.
The FDA has approved lirafugratinib (Lyrfigtu) for the treatment of adult patients with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.
Lanreotide injection, a generic formulation referencing lanreotide, was approved by the FDA for GEP-NETs management.
The FDA granted final approval to Lutetium Lu 177 dotatate biosimilar for patients with SSTR-positive GEP-NETs.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
3
Five Under 5: Top Oncology Videos for the Week of 9/20
4
FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC
5